<DOC>
	<DOCNO>NCT01677260</DOCNO>
	<brief_summary>This single centre , single-blind , randomize , balance , combine single dose study fast condition multiple dos study fed condition normal diabetic-meal , two-period , two-sequence cross-over study compare bioavailability metformin hydrochloride 500 mg extend release caplet ( test drug ) metformin hydrochloride 500 mg prolong release tablet ( reference formulation ) .</brief_summary>
	<brief_title>Bioequivalence Study Two Formulations 500 mg Metformin Extended Release Tablet</brief_title>
	<detailed_description>On Day 1 , obtain pharmacokinetic profile single dose , test reference drug give 200 mL water swallow without chew drug . For multiple dos administration Day 2 Day 5 , study drug administer regimen one tablet day , 30 minute breakfast . Time drug administration standardize participate subject throughout study period . From subject , Day 1 Day 5 blood sample draw 5 mL breakfast drug administration ; breakfast provide Day 2 Day 5 . Only Day 1 Day 5 drug administration , blood sample draw 5 mL 1 , 1.5 , 2 , 2.5 , 3 , 3.5 , 4 , 4.5 , 5 , 5.5 , 6 , 7 , 8 , 10 , 12 , 16 24 hour . The blood sample draw Day 1 use show single dose pharmacokinetic profile fast condition ; draw Day 5 use show multiple-dose-pharmacokinetic profile meal intake . One week first drug administration ( washout period ) , procedure repeat alternate drug . The plasma concentration metformin determine high performance liquid chromatography ultraviolet detection ( HPLC-UV ) . The pharmacokinetic parameter assess single dose study AUCt , AUCinf , Cmax , tmax , t1/2 . The pharmacokinetic parameter assess multiple dos study steady state phase AUCtau , Cmax , Cmin , t1/2 .</detailed_description>
	<mesh_term>Metformin</mesh_term>
	<criteria>Male female subject absence significant disease clinically significant abnormal laboratory value laboratory evaluation , medical history physical examination screening . Age 18 55 year Preferably nonsmoker smoke less 10 cigarette per day Able participate , communicate well investigator willing provide write informed consent participate study . BMI 18 25 kg/m2 Vital sign ( 10 minute rest ) within follow range : SBP 100 120 mmHg DBP 60 80 mmHg Pulse rate 60 90 bpm Personal/family history allergy hypersensitivity contraindication metformin hydrochloride biguanides ally drug . Pregnant lactate woman woman childbearing potential without adequate contraception Any major illness past 90 day clinically significant ongoing chronic medical illness Clinically significant illness within 4 week prior administration study medication Presence clinically significant abnormal value screen Positive Hepatitis B surface antigen ( HBsAg ) , antiHCV , antiHIV Clinically significant haematology abnormality Clinically significant electrocardiogram ( ECG ) abnormalities Any surgical medical condition ( present history ) might significantly alter absorption , distribution , metabolism excretion study drug History drug ( cocaine , amphetamine , opiate , cannabis ) alcohol abuse within 12 month prior screen study Participation clinical trial within past 90 day History bleed coagulative disorder History presence asthma bronchial related bronchospastic condition History seizure , epilepsy kind neurological disorder History difficulty donate blood difficulty vein puncture leave right arm A donation loss 500 mL ( ) blood within 3 month study 's first dose day Intake prescription nonprescription drug , food supplement herbal medicine within 14 day study 's first dose day Any food allergy , intolerance , restriction special diet opinion Research Physician , could contraindicate subject 's participation study Any reason opinion Research Physician , would prevent subject participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Biguanide</keyword>
	<keyword>anti-hyperglycaemic</keyword>
	<keyword>bioavailability</keyword>
	<keyword>bioequivalence</keyword>
	<keyword>metformin</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>